Basic information
Biomarker: Ribosomal DNA methylation
Biomarker subtype: gene
Clinical application: prognosis(unfavorable)
Histology type: endometrial carcinoma
Cohort characteristics
Country: USA
Region: St. Louis
Followed up time : 35.8 months
Protocol age: 66
Control age: 78
| Total number | Group I | Group I number | Group II | Group II number | Group III | Group III number | Group IV | Group IV number |
|---|---|---|---|---|---|---|---|---|
| 215 | EC | 215 | Caucasian | 176 | African-American | 39 |
Sample information
Sample type : tissue
Clinical method: Southern blot analysis
Expression pattern : low-level
Expression elevation: Disputed samples (15% or 7%) were reviewed in a group fashion without knowledge of the clinical features, and a consensus was reached. Methylation of rDNA was classified as minimal, intermediate, or extensive. Samples with minimal rRNA methylation had no evidence of EcoRI/HpaII DNA fragments greater than an arbitrarily assigned size of approximately 1.5 kilobases (kb). Tumors were assigned the category of intermediate methylation if no fragments measuring > 4 kb were evident. The category of extensive methylation was assigned to samples in which fragments of≥ 4.0 kb were evident.
Disease information
Statictics: Median
Protocol age: 66
Control age: 78
Related information
Description: Ribosomal DNA methylation in patients with endometrial carcinoma: an independent prognostic marker.
